Target therapy for high-risk neuroblastoma treatment: integration of regulatory and scientific tools is needed

Target therapy for high-risk neuroblastoma treatment: integration of regulatory and scientific tools is needed

IntroductionSeveral new active substances (ASs) targeting neuroblastoma (NBL) are under study. We aim to describe the developmental and regulatory status of a sample of ASs targeting NBL to underline the existing regulatory gaps in product development and to discuss possible improvements.MethodsThe...

Full description

Bibliographic Details
Main Authors: Adriana Ceci, Rosa Conte, Antonella Didio, Annalisa Landi, Lucia Ruggieri, Viviana Giannuzzi, Fedele Bonifazi
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Medicine
Subjects:
neuroblastoma
rare diseases
drug development
target therapy
pediatric regulation
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1113460/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2023.1113460/full

Similar Items